Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in Lysosomes

被引:272
作者
Lovejoy, David B. [1 ]
Jansson, Patric J. [1 ]
Brunk, Ulf T. [1 ,2 ]
Wong, Jacky [1 ]
Ponka, Prem [3 ]
Richardson, Des R. [1 ]
机构
[1] Univ Sydney, Dept Pathol, Sydney, NSW 2006, Australia
[2] Linkoping Univ, Dept Pharmacol, S-58185 Linkoping, Sweden
[3] Lady Davis Inst, Montreal, PQ, Canada
基金
英国医学研究理事会;
关键词
IRON CHELATORS; CANCER-CELLS; TRANSFERRIN; INHIBITION; APOPTOSIS; POTENT; AGENTS; DEATH;
D O I
10.1158/0008-5472.CAN-11-1218
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The metal-chelating compound Dp44mT is a di-2-pyridylketone thiosemicarbazone (DpT) which displays potent and selective antitumor activity. This compound is receiving translational attention, but its mechanism is poorly understood. Here, we report that Dp44mT targets lysosome integrity through copper binding. Studies using the lysosomotropic fluorochrome acridine orange established that the copper-Dp44mT complex (Cu[Dp44mT]) disrupted lysosomes. This targeting was confirmed with pepstatin A-BODIPY FL, which showed redistribution of cathepsin D to the cytosol with ensuing cleavage of the proapoptotic BH3 protein Bid. Redox activity of Cu[Dp44mT] caused cellular depletion of glutathione, and lysosomal damage was prevented by cotreatment with the glutathione precursor N-acetylcysteine. Copper binding was essential for the potent antitumor activity of Dp44mT, as coincubation with nontoxic copper chelators markedly attenuated its cytotoxicity. Taken together, our studies show how the lysosomal apoptotic pathway can be selectively activated in cancer cells by sequestration of redox-active copper. Our findings define a novel generalized strategy to selectively target lysosome function for chemotherapeutic intervention against cancer. Cancer Res; 71(17); 5871-80. (C) 2011 AACR.
引用
收藏
页码:5871 / 5880
页数:10
相关论文
共 32 条
[1]
ASCHWOODSMITH MJ, 1967, ANN NY ACAD SCI, V141, P41
[2]
Bid: a Bax-like BH3 protein [J].
Billen, L. P. ;
Shamas-Din, A. ;
Andrews, D. W. .
ONCOGENE, 2008, 27 (Suppl 1) :S93-S104
[3]
Brewer GJ, 2000, CLIN CANCER RES, V6, P1
[4]
Chalah A, 2008, ADV EXP MED BIOL, V615, P25, DOI 10.1007/978-1-4020-6554-5_3
[5]
Probing the cathepsin D using a BODIPY EL-pepstatin A: applications in fluorescence polarization and microscopy [J].
Chen, CS ;
Chen, WNU ;
Zhou, MJ ;
Arttamangkul, S ;
Haugland, RP .
JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, 2000, 42 (03) :137-151
[6]
Role and regulation of autophagy in cancer [J].
Chen, Ning ;
Karantza-Wadsworth, Vassiliki .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2009, 1793 (09) :1516-1523
[7]
DEDUVE C, 1983, EUR J BIOCHEM, V137, P391, DOI 10.1111/j.1432-1033.1983.tb07841.x
[8]
DELMAESTRO R, 1980, ACTA PHYSL SCAND S, V492, P91
[9]
Elevated copper and oxidative stress in cancer cells as a target for cancer treatment [J].
Gupte, Anshul ;
Mumper, Russell J. .
CANCER TREATMENT REVIEWS, 2009, 35 (01) :32-46
[10]
The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: An EPR study [J].
Jansson, Patric J. ;
Hawkins, Clare L. ;
Lovejoy, David B. ;
Richardson, Des R. .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2010, 104 (11) :1224-1228